JP7693189B2 - 癌治療のためのｔ細胞の活性化方法 - Google Patents

癌治療のためのｔ細胞の活性化方法 Download PDF

Info

Publication number
JP7693189B2
JP7693189B2 JP2020507103A JP2020507103A JP7693189B2 JP 7693189 B2 JP7693189 B2 JP 7693189B2 JP 2020507103 A JP2020507103 A JP 2020507103A JP 2020507103 A JP2020507103 A JP 2020507103A JP 7693189 B2 JP7693189 B2 JP 7693189B2
Authority
JP
Japan
Prior art keywords
cancer
cells
antigen
present
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020507103A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020532957A5 (https=
JP2020532957A (ja
Inventor
ホ キム、チョン
ソク キム、ポム
Original Assignee
グッド ティー セルズ、 インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グッド ティー セルズ、 インコーポレイテッド filed Critical グッド ティー セルズ、 インコーポレイテッド
Publication of JP2020532957A publication Critical patent/JP2020532957A/ja
Publication of JP2020532957A5 publication Critical patent/JP2020532957A5/ja
Priority to JP2023093867A priority Critical patent/JP2023113855A/ja
Application granted granted Critical
Publication of JP7693189B2 publication Critical patent/JP7693189B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4201—Neoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/869—Herpesviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2304—Interleukin-4 (IL-4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2312—Interleukin-12 (IL-12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2321—Interleukin-21 (IL-21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1107—B cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1114—T cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1121—Dendritic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1157—Monocytes, macrophages
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2020507103A 2017-08-10 2018-08-10 癌治療のためのｔ細胞の活性化方法 Active JP7693189B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023093867A JP2023113855A (ja) 2017-08-10 2023-06-07 癌治療のためのｔ細胞の活性化方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2017-0101800 2017-08-10
KR20170101800 2017-08-10
PCT/KR2018/009225 WO2019031939A2 (ko) 2017-08-10 2018-08-10 암 치료를 위한 t 세포의 활성화 방법

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023093867A Division JP2023113855A (ja) 2017-08-10 2023-06-07 癌治療のためのｔ細胞の活性化方法

Publications (3)

Publication Number Publication Date
JP2020532957A JP2020532957A (ja) 2020-11-19
JP2020532957A5 JP2020532957A5 (https=) 2021-09-09
JP7693189B2 true JP7693189B2 (ja) 2025-06-17

Family

ID=65271692

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020507103A Active JP7693189B2 (ja) 2017-08-10 2018-08-10 癌治療のためのｔ細胞の活性化方法
JP2020507093A Active JP7364237B2 (ja) 2017-08-10 2018-08-10 癌治療のためのｔ細胞の活性化方法
JP2023093867A Withdrawn JP2023113855A (ja) 2017-08-10 2023-06-07 癌治療のためのｔ細胞の活性化方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020507093A Active JP7364237B2 (ja) 2017-08-10 2018-08-10 癌治療のためのｔ細胞の活性化方法
JP2023093867A Withdrawn JP2023113855A (ja) 2017-08-10 2023-06-07 癌治療のためのｔ細胞の活性化方法

Country Status (7)

Country Link
US (3) US11918634B2 (https=)
EP (2) EP3666887A4 (https=)
JP (3) JP7693189B2 (https=)
KR (5) KR102148866B1 (https=)
CN (2) CN110997903B (https=)
BR (1) BR112020002816A2 (https=)
WO (2) WO2019031939A2 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3922642A4 (en) * 2019-02-08 2023-03-29 Good T Cells, Inc. METHOD OF ACTIVATING T LYMPHOCYTES FOR THE TREATMENT OF CANCER
EP3927361A4 (en) * 2019-02-21 2022-11-30 Ramot at Tel-Aviv University Ltd. TREATMENT OF DISEASES WITH MULTIMERIC PEPTIDES
KR102182555B1 (ko) * 2019-03-14 2020-11-24 한국과학기술연구원 T 세포 면역 반응 활성화를 위한 암 치료용 암항원 발굴 플랫폼
KR102335916B1 (ko) * 2019-04-22 2021-12-08 한국과학기술연구원 인간 백혈구 항원 a02:01 대립유전자에 특이적으로 결합하는 펩타이드 및 이의 용도
KR102322832B1 (ko) * 2019-04-22 2021-11-12 한국과학기술연구원 인간 백혈구 항원 a24:02 대립유전자에 특이적으로 결합하는 펩타이드 및 이의 용도
US20220364079A1 (en) * 2019-09-23 2022-11-17 Dana-Farber Cancer Institute, Inc. Methods of high-throughput identification of t cell epitopes by capturing cytokines on the surface of antigen-presenting cells
KR20210102089A (ko) 2020-02-11 2021-08-19 주식회사 리스큐어바이오사이언시스 미성숙 수지상 세포의 성숙화 유도를 이용한 암의 예방 또는 치료용 조성물
CN116018158A (zh) * 2020-04-30 2023-04-25 转化基因组学研究所 新抗原知情的肿瘤浸润性淋巴细胞癌免疫疗法
GB202010095D0 (en) * 2020-07-01 2020-08-12 Tcer Ab Immunotherapy
KR20220118225A (ko) 2021-02-18 2022-08-25 주식회사 리스큐어바이오사이언시스 미성숙 수지상 세포의 성숙화 유도를 이용한 암의 예방 또는 치료용 조성물
KR20220131170A (ko) 2021-03-19 2022-09-27 주식회사 리스큐어바이오사이언시스 미성숙 수지상 세포의 성숙화 유도를 이용한 암의 예방 또는 치료용 조성물
CN114230655B (zh) * 2021-03-24 2025-02-25 深圳市新靶向生物科技有限公司 一种与食道癌驱动基因突变相关的抗原肽组合及其应用
US20250313801A1 (en) * 2022-05-26 2025-10-09 Suzhou Ersheng Biomedical Co., Ltd. Specific t cell for preventing or treating cancer, and preparation method thereof
WO2024151124A1 (ko) * 2023-01-12 2024-07-18 주식회사 이뮤노맥스 항암능이 우수한 기억 t 세포 유래 면역세포치료제의 제조방법
WO2025240737A1 (en) * 2024-05-16 2025-11-20 Rutgers, The State University Of New Jersey Methods of producing memory t cells in vitro and their use in immunotherapy

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005530493A (ja) 2002-04-22 2005-10-13 レコファーマ アーベー ムチン融合ポリペプチドワクチン、組成物およびそれらの使用方法
JP2007117023A (ja) 2005-10-28 2007-05-17 Igaku Seibutsugaku Kenkyusho:Kk エプスタイン−バールウイルス感染細胞を特異的に攻撃する細胞傷害性ｔ細胞エピトープペプチド及びその用途
JP2013502235A (ja) 2009-08-24 2013-01-24 ベイラー カレッジ オブ メディスン 複数の腫瘍抗原または複数のウイルスに対する特異的ｃｔｌ株の作製［関連出願の相互参照］
WO2016044530A1 (en) 2014-09-17 2016-03-24 The Johns Hopkins University Reagents and methods for identifying, enriching, and/or expanding antigen-specific t cells
WO2016172722A1 (en) 2015-04-23 2016-10-27 Nantomics, Llc Cancer neoepitopes
WO2016187508A2 (en) 2015-05-20 2016-11-24 The Broad Institute Inc. Shared neoantigens

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6037135A (en) * 1992-08-07 2000-03-14 Epimmune Inc. Methods for making HLA binding peptides and their uses
GB0214528D0 (en) 2002-06-24 2002-08-07 Univ Aberdeen Materials and methods for induction of immune tolerance
US7619058B2 (en) * 2004-01-20 2009-11-17 Aichi Prefecture Epitope/peptide recognized by HLA-A2402-restricted Ep-CAM-specific CTL and use of the same
JP4628208B2 (ja) * 2004-08-10 2011-02-09 オンコセラピー・サイエンス株式会社 Ｃｘａｄｒｌ１またはｇｃｕｄ１タンパク質を発現する胃癌または結腸直腸癌の治療のためのペプチドワクチン
TWI596109B (zh) * 2007-02-21 2017-08-21 腫瘤療法 科學股份有限公司 表現腫瘤相關抗原之癌症的胜肽疫苗
KR20100058509A (ko) * 2007-07-31 2010-06-03 메디뮨 엘엘씨 다중특이적 에피토프 결합 단백질 및 이의 용도
CA2730742C (en) 2008-07-16 2017-05-23 Baylor Research Institute Hiv vaccine based on targeting maximized gag and nef to dendritic cells
CN101643497A (zh) * 2009-09-15 2010-02-10 南京医科大学 Lmp2a蛋白来源的hla-a2限制性表位多肽及其用途
GB0917090D0 (en) 2009-09-29 2009-11-11 Ucl Biomedica Plc T-cell receptor
JP6130307B2 (ja) * 2011-03-17 2017-05-17 ザ ユニバーシティ オブ バーミンガム 再指向性免疫療法
CN104769104A (zh) 2011-12-12 2015-07-08 细胞药物有限公司 扩大t细胞的方法
GB201312133D0 (en) * 2013-07-05 2013-08-21 Univ Birmingham Immunotherapy
CN107709351A (zh) 2015-06-17 2018-02-16 株式会社医学生物学研究所 细胞毒性t细胞表位肽及其用途
AU2016339924B2 (en) * 2015-10-12 2020-01-02 Nantomics, Llc Compositions and methods for viral cancer neoepitopes
CA3003251A1 (en) * 2015-10-12 2017-04-20 Nantomics, Llc Systems, compositions, and methods for discovery of msi and neoepitopes that predict sensitivity to checkpoint inhibitors
RU2729116C2 (ru) * 2015-12-16 2020-08-04 Гритстоун Онколоджи, Инк. Идентификация, производство и применение неоантигенов
EP3463398A4 (en) * 2016-05-25 2020-03-11 The Council of the Queensland Institute of Medical Research IMMUNE CONTROL POINT INHIBITORS AND CYTOTOXIC T-LYMPHOCYTES FOR THE TREATMENT OF CANCER
PT3488443T (pt) * 2016-07-20 2021-09-24 BioNTech SE Seleção de neoepítopos como alvos específicos da doença para terapia com eficácia melhorada

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005530493A (ja) 2002-04-22 2005-10-13 レコファーマ アーベー ムチン融合ポリペプチドワクチン、組成物およびそれらの使用方法
JP2007117023A (ja) 2005-10-28 2007-05-17 Igaku Seibutsugaku Kenkyusho:Kk エプスタイン−バールウイルス感染細胞を特異的に攻撃する細胞傷害性ｔ細胞エピトープペプチド及びその用途
JP2013502235A (ja) 2009-08-24 2013-01-24 ベイラー カレッジ オブ メディスン 複数の腫瘍抗原または複数のウイルスに対する特異的ｃｔｌ株の作製［関連出願の相互参照］
WO2016044530A1 (en) 2014-09-17 2016-03-24 The Johns Hopkins University Reagents and methods for identifying, enriching, and/or expanding antigen-specific t cells
WO2016172722A1 (en) 2015-04-23 2016-10-27 Nantomics, Llc Cancer neoepitopes
WO2016187508A2 (en) 2015-05-20 2016-11-24 The Broad Institute Inc. Shared neoantigens

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PLOS ONE (2016) Vol.11, No.11, e0166372, pp.1-18

Also Published As

Publication number Publication date
US20200289630A1 (en) 2020-09-17
US20210009952A1 (en) 2021-01-14
KR20220136957A (ko) 2022-10-11
KR20190017705A (ko) 2019-02-20
JP2020532957A (ja) 2020-11-19
CN110997903A (zh) 2020-04-10
WO2019031938A3 (ko) 2019-07-04
JP2023113855A (ja) 2023-08-16
KR102190890B1 (ko) 2020-12-15
KR102148866B1 (ko) 2020-10-14
US11918634B2 (en) 2024-03-05
KR20190017702A (ko) 2019-02-20
CN110997903B (zh) 2024-03-29
WO2019031939A3 (ko) 2019-07-18
EP3666887A2 (en) 2020-06-17
BR112020002816A2 (pt) 2020-08-04
CN111433355A (zh) 2020-07-17
CN111433355B (zh) 2024-03-29
JP2020532956A (ja) 2020-11-19
US11969463B2 (en) 2024-04-30
WO2019031938A2 (ko) 2019-02-14
US20240156927A1 (en) 2024-05-16
JP7364237B2 (ja) 2023-10-18
EP3666888A4 (en) 2021-09-01
KR20200141424A (ko) 2020-12-18
KR20200102402A (ko) 2020-08-31
EP3666888A2 (en) 2020-06-17
WO2019031939A2 (ko) 2019-02-14
EP3666887A4 (en) 2021-09-01

Similar Documents

Publication Publication Date Title
JP7693189B2 (ja) 癌治療のためのｔ細胞の活性化方法
US7651686B2 (en) Enhancement of immune responses by 4-1bb-binding agents
JP7002769B2 (ja) ウイルス特異的ｔ細胞の活性化および拡大のためのプラットフォーム
KR20230018376A (ko) 키메라 항원 수용체를 발현하는 바이러스 특이적 면역세포를 사용한 암의 치료 및 예방
JP2025106402A (ja) がん治療のためのｔ細胞の活性化方法
CN117529551A (zh) 表达嵌合抗原受体的病毒特异性免疫细胞
Mansoor et al. Genetically Modified T Cell Therapy Optimisation of the Chimeric T Cell Receptor for Cancer Therapy
Bollard et al. Adoptive Immunotherapy
Berg et al. Tumor Immunology

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210730

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210730

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220613

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220622

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220921

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221122

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230607

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230608

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230628

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230804

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250529

R150 Certificate of patent or registration of utility model

Ref document number: 7693189

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150